Results 221 to 230 of about 30,146 (272)

Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial. [PDF]

J Clin Oncol
Mohty M, Socié G, Szer J, Niederwieser D, Butler J, Wagner-Drouet E, Or R, Rovenvald-Zuckerman T, Bozdag SC, Forcade E, Grillo G, Kröger N, Stölzel F, Russo D, Sanz J, Sarkar R, Stefanelli T, Wilke C, Zeiser R, von Bubnoff N.   +19 more
europepmc   +1 more source

Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis

, 2014
Chul Won Jung, Lee‐Yung Shih, Zhijian Xiao, Jin Jie, Hsin‐An Hou, Xin Du, Ming-Chung Wang, Seonyang Park, Ki‐Seong Eom, Kenji Oritani, Shinichiro Okamoto, Tetsuzo Tauchi, Jin Seok Kim, Daobin Zhou, Shigeki Saito, Junmin Li, Hiroshi Handa, Jianyong Li, Kohshi Ohishi, Ming Hou, Wu Depei, Katsuto Takenaka, Ting Liu, Yu Hu, Taro Amagasaki, Kazuo Itô, Prashanth Gopalakrishna, Koichi Akashi   +27 more
openalex   +2 more sources

Histone deacetylase 3 promotes hypoxia-induced human pulmonary arterial smooth muscle cell proliferation by modulating the CSF2-JAK2-STAT5 signaling pathway. [PDF]

Hum Cell
Zhang J, Fan Y, Gao Y, Jin Y.
europepmc   +1 more source

Corrigendum to Ruxolitinib improves hematopoietic regeneration by restoring mesenchymal stromal cell function in acute graft-versus-host disease. [PDF]

J Clin Invest
Lin Y, Gu Q, Lu S, Pan Z, Yang Z, Li Y, Yang S, Lv Y, Zheng Z, Sun G, Gou F, Xu C, Zhao X, Wang F, Wang C, Yuan S, Xie X, Cao Y, Liu Y, Gu W, Cheng T, Cheng H, Hu X.   +22 more
europepmc   +1 more source

Ruxolitinib in the Treatment of Vitiligo. The Importance of the JAK STAT Pathway

JL López Estebaranz, G Segurado Miravalles, Sandra Ros   +2 more
openalex   +1 more source

Combined MEK and JAK inhibition reduces osteopontin plasma level and bone marrow fibrosis in a myelofibrosis mouse model. [PDF]

Blood Cancer J
Tavernari L, Bertesi M, Neroni A, Papa E, Rontauroli S, Bianchi E, Mirabile M, Norfo R, Parenti S, Tombari C, Carretta C, Malerba M, Fabbiani L, Guglielmelli P, Losi L, Tagliafico E, Vannucchi AM, Manfredini R, MYNERVA (MYeloid NEoplasms Research Venture AIRC) investigators.   +18 more
europepmc   +1 more source

Hyper-activation of STAT3 sustains progression of non-papillary basal-type bladder cancer via FOSL1 regulome [PDF]

, 2019
et al,, Vermi, William
core   +1 more source

Immune Checkpoint Inhibitor-Induced Concomitant Polyradiculoneuritis and Myocarditis With Positive Anti-Titin Antibodies: A Case Report and Literature Review. [PDF]

Crit Care Explor
Laslandes M, Piron B, Cap M, Courant A, Canet E, Benguerfi S.   +5 more
europepmc   +1 more source

Cytopenias and Large Splenomegaly are Main Drivers of Poor Outcome after Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis

Francesca Palandri, Massimo Breccia, Erika Morsia, Elena Maria Elli, Giulia Benevolo, Mario Tiribelli, Eloise Beggiato, Mirko Farina, Giovanni Caocci, Novella Pugliese, Alessia Tieghi, Monica Crugnola, Gianni Binotto, Francesco Cavazzini, Elisabetta Abruzzese, Alessandro Isidori, Alessandra Dedola, Alessandra Iurlo, Roberto M. Lemoli, Daniela Cilloni, Monica Bocchia, Florian H. Heidel, Massimiliano Bonifacio, Giuseppe A. Palumbo, Filippo Branzanti   +24 more
openalex   +1 more source